Disease · HP_0002015
Dysphagia
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. Dysphagia. Diseases, record HP_0002015. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/HP_0002015
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Name
- Dysphagia
- Open Targets ID
- HP_0002015
- Other names
- Difficulty swallowing, Poor swallowing, Swallowing difficulties, Swallowing difficulty
- Highest stage of its drugs
- Phase 3, for 9 of its 29 drugs, from ClinicalTrials.gov
Source Open Targets
Drugs29
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| DEXAMETHASONE | CHEMBL384467 | Small molecule | Phase 3 | ClinicalTrials.gov | 6 | 6 | 6 | Drugs and targets |
| BENRALIZUMAB | CHEMBL1742991 | Antibody | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| BUDESONIDE | CHEMBL1370 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| CISPLATIN | CHEMBL11359 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| FLUOROURACIL | CHEMBL185 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| HUMAN IMMUNOGLOBULIN G | CHEMBL1201599 | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets | |
| KETOROLAC | CHEMBL469 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| MIGLUSTAT | CHEMBL1029 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| NICERGOLINE | CHEMBL1372950 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| BOTULINUM TOXIN TYPE A | CHEMBL4297862 | Protein | Phase 2/3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
1 to 10 of 29
See all 29 drugsTargets76
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| NR3C1 | Glucocorticoid receptor | 4 | Glucocorticoid receptor agonist | Phase 3 | https://conductscience.org/library/genes/2908 | Drugs and targets |
| SCN10A | Sodium channel alpha subunit | 2 | Sodium channel alpha subunit blocker | Unknown | https://conductscience.org/library/genes/6336 | Drugs and targets |
| SCN11A | Sodium channel alpha subunit | 2 | Sodium channel alpha subunit blocker | Unknown | https://conductscience.org/library/genes/11280 | Drugs and targets |
| SCN1A | Sodium channel alpha subunit | 2 | Sodium channel alpha subunit blocker | Unknown | https://conductscience.org/library/genes/6323 | Drugs and targets |
| SCN2A | Sodium channel alpha subunit | 2 | Sodium channel alpha subunit blocker | Unknown | https://conductscience.org/library/genes/6326 | Drugs and targets |
| SCN3A | Sodium channel alpha subunit | 2 | Sodium channel alpha subunit blocker | Unknown | https://conductscience.org/library/genes/6328 | Drugs and targets |
| SCN4A | Sodium channel alpha subunit | 2 | Sodium channel alpha subunit blocker | Unknown | https://conductscience.org/library/genes/6329 | Drugs and targets |
| SCN5A | Sodium channel alpha subunit | 2 | Sodium channel alpha subunit blocker | Unknown | https://conductscience.org/library/genes/6331 | Drugs and targets |
| SCN7A | Sodium channel alpha subunit | 2 | Sodium channel alpha subunit blocker | Unknown | https://conductscience.org/library/genes/6332 | Drugs and targets |
| SCN8A | Sodium channel alpha subunit | 2 | Sodium channel alpha subunit blocker | Unknown | https://conductscience.org/library/genes/6334 | Drugs and targets |
1 to 10 of 76
See all 76 targetsTrials37
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02605837 | A Study in Adolescents and Adults With Eosinophilic Esophagitis (EoE) Measuring Histologic Response and Determine if Reduction in Dysphagia is Achieved | Phase 3 | 318 | 2020-03-16 | Eosinophilic Esophagitis (EoE) | BUDESONIDE | Its record names the disease | ClinicalTrials.gov |
| NCT04543409 | A Study of Benralizumab in Patients With Eosinophilic Esophagitis | Phase 3 | 211 | 2023-11-18 | Eosinophilic Esophagitis | BENRALIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT02728752 | Study Evaluating Efficacy and Safety of Octagam 10% in Patients With Dermatomyositis (Idiopathic Inflammatory Myopathy) | Phase 3 | 95 | 2021-04-21 | Dermatomyositis | HUMAN IMMUNOGLOBULIN G | Its record names the disease | ClinicalTrials.gov |
| NCT02577991 | Effect of Local Steroid Application on a Cervical Plate Versus Intravenous Steroids on Dysphagia Following Anterior Cervical Discectomy and Fusion (ACDF) | Not applicable | 80 | 2019-05-30 | Cervical Spine | DEXAMETHASONE, TRIAMCINOLONE | Its record names the disease | ClinicalTrials.gov |
| NCT02416934 | Dysphagia Following Anterior Cervical Spine Surgery; Steroid vs Saline | Not applicable | 74 | 2018-03-30 | Dysphagia | DEXAMETHASONE | Its record names the disease | ClinicalTrials.gov |
| NCT03656380 | Mepo for Eosinophilic Esophagitis (EoE) Study | Phase 2 | 66 | 2023-06-23 | EoE, Eosinophilic Esophagitis | MEPOLIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT04614974 | Initiation of Acid Suppression Therapy Prospective Outcomes for Laryngomalacia | Phase 1/2 | 65 | 2025-07-20 | Laryngomalacia, Gastro Esophageal Reflux | FAMOTIDINE | Its record names the disease | ClinicalTrials.gov |
| NCT00880906 | Study of the Efficiency of Esophageal Dilation on Patient With Eosinophilic Esophagitis | Not applicable | 50 | 2014-05-26 | Suspected Eosinophilic Esophagitis | FLUTICASONE PROPIONATE | Its record names the disease | ClinicalTrials.gov |
| NCT04650893 | The Effect of IV NSAID's and Corticosteroids on Dysphasia and Dysphonia Following ASDF | Phase 3 | 33 | 2024-08-23 | Dysphagia, Dysphonia | DEXAMETHASONE, KETOROLAC | Its record names the disease | ClinicalTrials.gov |
| NCT01085903 | Identifying and Treating Arousal Related Deficits in Neglect and Dysphagia | Phase 2 | 28 | 2016-10-18 | Spatial Neglect, Dysphagia | MODAFINIL | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 37
See all 37 trialsComparisons in its trials15
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Oral Budesonide Suspension (OBS) vs Placebo: deaths from any cause | 0 of 213 | 0 of 105 | 318 | NCT02605837 | Trial comparisons |
| Oral Budesonide Suspension (OBS) vs Placebo: Number of Participants With Treatment-Emergent Adverse Events (AE) | 130 of 213 | 64 of 105 | 318 | NCT02605837 | Trial comparisons |
| Oral Budesonide Suspension (OBS) vs Placebo: serious adverse events | 2 of 213 | 1 of 105 | 318 | NCT02605837 | Trial comparisons |
| Overall Period Octagam vs First Period Placebo: deaths from any cause | 0 of 95 | 0 of 48 | 143 | NCT02728752 | Trial comparisons |
| Overall Period Octagam vs First Period Placebo: serious adverse events | 14 of 95 | 2 of 48 | 143 | NCT02728752 | Trial comparisons |
| Octagam10% vs Placebo: Measure the Number of Patients Who Had an Increase of ≥20 Points on the Total Improvement Score (TIS) | 37 of 47 | 21 of 48 | 95 | NCT02728752 | Trial comparisons |
| Speech Language Therapy Alone vs Speech Language Therapy and Acid Suppression Therapy: Number of Participants With the Need for Supraglottoplasty Surgery (Escalation of Treatment) up to 1 Year | 2 of 34 | 1 of 31 | 65 | NCT04614974 | Trial comparisons |
| Speech Language Therapy Alone vs Speech Language Therapy and Acid Suppression Therapy: deaths from any cause | 0 of 34 | 0 of 31 | 65 | NCT04614974 | Trial comparisons |
Speech Language Therapy Alone vs Speech Language Therapy and Acid Suppression Therapy: Number of Participants With the Need for a Different Acid Suppression Therapy Medication (Other Than Famotidine) From the Day After the Consult up to the 3 Month Follow up Appointment | 0 of 34 | 2 of 31 | 65 | NCT04614974 | Trial comparisons |
| Speech Language Therapy Alone vs Speech Language Therapy and Acid Suppression Therapy: serious adverse events | 3 of 34 | 3 of 31 | 65 | NCT04614974 | Trial comparisons |
1 to 10 of 15
See all 15 comparisons in its trialsPapers from its trials22
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
| PMID | Listed as | Trials listing it | Source |
|---|---|---|---|
| 22476655 | RESULT | 1 | PubMed |
| 41782152 | DERIVED | 1 | PubMed |
| 41711386 | DERIVED | 1 | PubMed |
| 40762274 | DERIVED | 1 | PubMed |
| 40616720 | DERIVED | 1 | PubMed |
| 39918968 | DERIVED | 1 | PubMed |
| 39777591 | DERIVED | 1 | PubMed |
| 39735351 | DERIVED | 1 | PubMed |
| 39631042 | DERIVED | 1 | PubMed |
| 38924732 | DERIVED | 1 | PubMed |
1 to 10 of 22
See all 22 papers from its trialsData dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/HP_0002015
GET https://conductscience.org/api/diseases/v1/HP_0002015/drugs?page=2